Seres Therapeutics Inc (MCRB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Seres Therapeutics Inc (MCRB) has a cash flow conversion efficiency ratio of -0.617x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.36 Million) by net assets ($26.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Seres Therapeutics Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Seres Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Seres Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Seres Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Seres Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Newbridge Acquisition Limited Class A Ordinary Share
NASDAQ:NBRG
|
0.115x |
|
tsh biopharmoration Ltd
TWO:8432
|
0.027x |
|
Italian-Thai Development Public Company Limited
BK:ITD
|
0.490x |
|
Westlin Corporation
NASDAQ:WSTN
|
-0.003x |
|
Farmsco
KO:036580
|
0.097x |
|
Alliance Witan Ord
LSE:ALW
|
0.007x |
|
Meta Biomed Co. Ltd
KQ:059210
|
0.009x |
|
Halmont Properties Corporation
V:HMT
|
0.011x |
Annual Cash Flow Conversion Efficiency for Seres Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Seres Therapeutics Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see MCRB company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $44.22 Million | $1.12 Million | 0.025x | +100.23% |
| 2024-12-31 | $13.78 Million | $-148.61 Million | -10.781x | -512.09% |
| 2023-12-31 | $-44.86 Million | $-117.35 Million | 2.616x | +112.33% |
| 2022-12-31 | $10.78 Million | $-228.82 Million | -21.220x | -41825.29% |
| 2021-12-31 | $131.51 Million | $6.69 Million | 0.051x | +109.49% |
| 2020-12-31 | $174.75 Million | $-93.61 Million | -0.536x | -133.83% |
| 2019-12-31 | $-48.32 Million | $-76.52 Million | 1.583x | +21.04% |
| 2018-12-31 | $-48.05 Million | $-62.85 Million | 1.308x | +205.14% |
| 2017-12-31 | $60.70 Million | $-75.52 Million | -1.244x | -475.73% |
| 2016-12-31 | $132.63 Million | $43.92 Million | 0.331x | +266.53% |
| 2015-12-31 | $205.39 Million | $-40.84 Million | -0.199x | -151.30% |
| 2014-12-31 | $-26.72 Million | $-10.36 Million | 0.388x | +104.60% |
| 2013-12-31 | $631.00K | $-5.32 Million | -8.433x | -1733.56% |
| 2012-12-31 | $6.36 Million | $-2.92 Million | -0.460x | -- |
About Seres Therapeutics Inc
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in pat… Read more